02:26:28 Europe / Stockholm

Bifogade filer

Kalender

2024-11-07 Kvartalsrapport 2024-Q3
2024-08-15 Kvartalsrapport 2024-Q2
2024-05-02 Kvartalsrapport 2024-Q1
2024-04-26 Ordinarie utdelning VIRO 0.00 DKK
2024-04-25 Årsstämma 2024
2024-03-21 Bokslutskommuniké 2023
2023-11-24 Extra Bolagsstämma 2023
2023-11-09 Kvartalsrapport 2023-Q3
2023-08-17 Kvartalsrapport 2023-Q2
2023-05-04 Kvartalsrapport 2023-Q1
2023-04-28 Ordinarie utdelning VIRO 0.00 DKK
2023-03-23 Bokslutskommuniké 2022
2022-11-10 Kvartalsrapport 2022-Q3
2022-08-18 Kvartalsrapport 2022-Q2
2022-05-04 Kvartalsrapport 2022-Q1
2022-04-29 Ordinarie utdelning VIRO 0.00 DKK
2022-04-28 Årsstämma 2022
2022-03-23 Bokslutskommuniké 2021
2021-11-11 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-04-29 Kvartalsrapport 2021-Q1
2021-04-28 Ordinarie utdelning VIRO 0.00 DKK
2021-04-27 Årsstämma 2021
2021-03-24 Bokslutskommuniké 2020
2020-10-27 Kvartalsrapport 2020-Q3
2020-08-13 Kvartalsrapport 2020-Q2
2020-06-19 Ordinarie utdelning VIRO 0.00 DKK
2020-06-18 Årsstämma 2020
2020-04-30 Kvartalsrapport 2020-Q1
2020-03-25 Bokslutskommuniké 2019
2019-10-28 Kvartalsrapport 2019-Q3
2019-08-21 Kvartalsrapport 2019-Q2
2019-04-29 Kvartalsrapport 2019-Q1
2019-04-26 Ordinarie utdelning VIRO 0.00 DKK
2019-04-25 Årsstämma 2019

Beskrivning

LandDanmark
ListaFirst North Denmark
SektorHälsovård
IndustriMedicinteknik
Virogates är verksamt inom medicinteknik. Idag innehas affärsverksamhet inom forskning och utveckling av biomarkörer och diagnostiska instrument för sjukvårdsindustrin. Produkterna säljs under olika varumärken och används vid identifiering, analys och vidarebehandling av sjukdomar, främst hjärt- och kärlsjukdomar, cancer och neurologiska sjukdomar. Bolaget etablerades 2001 och har sitt huvudkontor i Birkerød.
2019-12-13 11:49:07

13.12.2019 11:49:05 CET | ViroGates | Company Announcement

Company announcement no. 15-2019                                                                                                                         

Birkerød, 13 December 2019

ViroGates A/S (Nasdaq First North Growth Market Denmark: VIRO), who delivers blood test systems, primarily for acute care departments in hospitals, today announces that suPARnostic® TurbiLatex now will be made available for clinical decision making at Sygehus Lillebaelts two hospitals in Kolding and Vejle. Both hospitals use the cobas system from Roche Diagnostics, an instrument line that was validated by ViroGates for use of suPARnostic® TurbiLatex earlier this year.

The two hospitals have a total of 360 beds and sees a variety of medical and surgical patients. The two hospitals are both part of Hospital Lillebaelt and along with Middelfart hospital, the group is the second largest hospital unit in Region Syddanmark. In total the group has an uptake population of approximately 300,000 persons. The majority of acute care functions are handled at Kolding Hospital. Sygehus Lillebaelt is the overall administrative unit for the three hospitals.


Senior hospital physician, PhD Claus Lohman Brasen, Dept. of Biochemistry and Immunology, Lillebaelt Hospital, says: In the beginning of 2020 Lillebaelt Hospital will introduce the suPAR-analysis from Virogates as part of a large intensified diagnostic effort using a complete laboratory package initially including more than 100 tests. Artificial intelligence will be used to develop new standards for laboratory admittance protocols for emergency patients.

The suPARnostic® TurbiLatex assay will be analysed on the Roche Cobas c502 system in our centralized laboratory facilities in order to provide quick and reliable results in less than one hour from patient sampling to results in the hands of the clinicians. This is possible due to the generally automated laboratory facility using GLP-track as well as tempus600 transportation.”
 

CEO Jakob Knudsen, says in a comment: ”We are excited that two more hospitals in Denmark have decided to use suPARnostic® TurbiLatex as part of their tools to help guide patient triage and treatment. Vejle and Kolding hospitals stress the importance of getting quick and reliable results to help guide clinical decisions. This underpins the solidity of our new product as well as the ability to integrate with other hospital systems such as automated handling of blood samples.”

The announcement can be found at https://www.virogates.com/investor/announcements 

 

For further information contact:

CEO Jakob Knudsen

Tel. (+45) 2113 1336, Email: jk@virogates.com

ViroGates A/S

CVR-nr. 25734033

Blokken 45, DK-340 Birkerød

www.virogates.com

 

Lillebaelt Hospital

Claus Lohman Brasen,

Senior Hospital Physician, PhD

Biochemistry and Immunology

Lillebaelt Hospital, Denmark

claus.lohman.brasen@rsyd.dk

Phone. +45 79406955

  

Certified Advisor

Västra Hamnen Corporate Finance

Per Lönn

Tel. (+46) 40 200 250, Email: per.lonn@vhcorp.se

 

Disclaimer

Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.

Contacts

About ViroGates

ViroGates is an international medtech company developing and marketing prognostics products to improve patient care, reduce healthcare costs and empower clinical staff in the healthcare sector. Based on more than 600 clinical trials and studies, ViroGates’ suPARnostic® product range supports hospital professionals in making clinical decisions on hospitalization or discharge of acute care patients as well as detecting and assessing the severity of cardiovascular diseases, type 2 diabetes, cancer, etc. suPARnostic® TurbiLatex is available on Roche Diagnostics’ Cobas instruments and ViroGates works with partners to develop solutions for other platforms. Headquartered in Denmark, ViroGates’ sales force covers the Nordics, Germany, Spain, and France, while distributors serve other markets. www.virogates.com

Attachments